ArticleDiscover oncology2025
Application of Mendelian randomization and bioinformatic analysis to construct a prognostic model for thyroid cancer and perform pan-cancer analysis.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveThis study aimed to identify causal effects and potential molecular mechanisms of genes associated with THCA development.
methodsBioinformatic analyses were performed to identify differentially expressed genes (DEGs) associated with THCA. Subsequently, Mendelian randomization (MR) analysis was conducted using large-scale eQTL data and THCA GWAS summary statistics to screen for candidate genes. The intersection of DEGs and MR-derived candidate genes was used to determine DEGs with potential causal associations with thyroid carcinogenesis. Functional enrichment analysis, pathway analysis, and immune cell infiltration profiling were performed. External datasets were used for validation. Additionally, prognostic modeling and pan-cancer analyses of the candidate genes were conducted.
resultsIVW-based MR analysis revealed that elevated expression levels of ALOX15B [OR = 1.647, 95% CI (1.120-2.420), P < 0.05], TIAM1 [OR = 1.270, 95% CI (1.001-1.611), P < 0.05], and TMC6 [OR = 1.250, 95% CI (1.021-1.530), P < 0.05] were associated with an increased risk of THCA. Conversely, elevated expression of JUN [OR = 0.795, 95% CI (0.653-0.967), P < 0.05], PAPSS2 [OR = 0.779, 95% CI (0.608-1.000), P < 0.05], and RAP1GAP [OR = 0.895, 95% CI (0.810-0.989), P < 0.05] was associated with a reduced risk. Gene set enrichment analysis (GSEA) indicated that risk genes were enriched in proliferation- and metastasis-related pathways, such as extracellular matrix (ECM)-receptor interaction and cell adhesion molecules (CAMs). Findings from the training set were further validated experimentally and via external datasets. Additionally, candidate risk genes demonstrated associations with the development and progression of multiple tumor types.
conclusionThis study identified ALOX15B, TIAM1, and TMC6 as potential risk genes and JUN, PAPSS2, and RAP1GAP as protective genes in THCA. These genes may serve as promising biomarkers and therapeutic targets for THCA, offering novel insights into precision oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.